DDInter173 DDInter1676
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells. It is produced by recombinant DNA technology in a murine cell (NS0) expression system. Belimumab was first approved by the FDA on March 9, 2011, making it the newest drug to be approved for the treatment of SLE in more than 50 years. It is currently used to treat SLE and lupus nephritis.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Belimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Belimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Belimumab may lead to a major life threatening interaction when taken with Tofacitinib
Belimumab may lead to a major life threatening interaction when taken with Natalizumab